Skip to content

13F-HR filed by Casdin Capital, LLC

Casdin Capital, LLC filed this 13F-HR for the quarter ended 2016-06-30, filed 2016-08-15, with 27 holding rows worth $100,465,000.

Accession
0001172661-16-003861
Filed
2016-08-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2016

A holdings report, 27 entries on the cover page, a total value of $100,465,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $100,465,000 with VALUE read as thousands by filing date, 13F file number 028-17113. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SPARK THERAPEUTICS INC84652J103COM162,500$8,309,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM187,500$7,855,000thousands by filing date
Foundation Medicine Inc350465100COM390,000$7,277,000thousands by filing date
GLOBAL BLOOD THERAPEUTICS USD37890U108COM430,000$7,134,000thousands by filing date
LOXO ONCOLOGY INC548862101COM300,000$6,954,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM228,500$6,885,000thousands by filing date
BLUEPRINT MEDICINES CORP09627Y109COM340,000$6,885,000thousands by filing date
BLUEBIRD BIO INC09609G100COM122,500$5,303,000thousands by filing date
EVOLENT HEALTH INC CL A30050B101Stock239,500$4,598,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock72,500$4,023,000thousands by filing date
KITE PHARMA INC49803L109COM72,500$3,625,000thousands by filing date
GENMARK DIAGNOSTICS INC372309104COM415,000$3,611,000thousands by filing date
VOYAGER THERAPEUTICS INC92915B106COMMON STOCK322,500$3,544,000thousands by filing date
EPIZYME INC29428V104COM340,000$3,482,000thousands by filing date
CYTOMX THERAPEUTICS INC23284F105COMMON STOCK234,179$2,392,000thousands by filing date
MYOKARDIA INC62857M105COM179,029$2,220,000thousands by filing date
CLOVIS ONCOLOGY INC189464100COM150,000$2,058,000thousands by filing date
IGNYTA INC451731103COM375,000$2,033,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM65,000$1,958,000thousands by filing datecall
AVEXIS INC05366U100COM45,000$1,711,000thousands by filing date
TESARO INC881569107COM20,000$1,681,000thousands by filing date
SPDR SER TR78464A870S&P BIOTECH30,000$1,622,000thousands by filing dateput
Bristol-Myers Squibb Company110122108COM21,000$1,545,000thousands by filing date
DEXCOM INC COM252131107Stock15,000$1,190,000thousands by filing date
DEXCOM INC COM252131107Stock15,000$1,190,000thousands by filing dateput
SYROS PHARMACEUTICALS INC87184Q107COM50,000$908,000thousands by filing date
Medgenics Inc New58436Q203COM NEW85,000$472,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001172661-16-003861this filing2016-08-15acceptance time not in the bulk data set